烟酰胺核糖(Nicotinamide riboside) - 药物靶点：NAD+_在研适应症：共济失调毛细血管扩张，外周动脉疾病，急性发热性疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

NIAGEN、Nicotinamide riboside chloride、Nicotinamide-beta-riboside

+ [4]

靶点

NAD+

作用机制

NAD+调节剂(烟酰胺腺嘌呤二核苷酸调节剂)

治疗领域

免疫系统疾病神经系统疾病心血管疾病+ [5]

在研适应症

共济失调毛细血管扩张外周动脉疾病急性发热性疾病+ [3]

非在研适应症

头颈部肿瘤转移性乳腺癌转移性子宫内膜恶性肿瘤+ [2]

原研机构

Chromadex Corp.

在研机构

ChromaDex, Inc.福建医科大学附属第一医院（福建省皮肤病性病防治院、福建省皮肤病性病防治研究所）

Akershus Universitetssykehus HF

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床前

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C11H15N2O5

InChIKeyJLEBZPBDRKPWTD-TURQNECASA-O

CAS号1341-23-7

关联

29

项与烟酰胺核糖相关的临床试验

NCT06567717 / Not yet recruiting临床2期IIT

Feasibility of a Decentralized Double-Blind Randomized Controlled Trial of Zinc and Nicotinamide Riboside for the Treatment of Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are:
Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF.
Participants will:
Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.

开始日期2025-01-01

申办/合作机构

Cedars-Sinai Health System

NCT04614714 / Not yet recruiting临床2/3期IIT

Nicotinamide Riboside and Milk Production in the NICU

Breastfeeding has well-established immunity and developmental benefits for newborns, yet mothers of preterm infants often struggle to provide sufficient breast milk. The investigators hypothesize that supplementing mothers of preterm infants with nicotinamide riboside (NR) during early postpartum will result in increased milk production. NR is a unique precursor to NAD+, which functions in whole-body metabolism, including that which supports the elevated energy demands of lactation. In lactating rats, NR supplementation improved milk quantity and quality, with metabolic benefits for the mother and lasting protective advantages for the offspring. No studies have been conducted to date that explore the short- or long-term use of NR for increasing milk supply in lactating women. This study will follow a small cohort of women and very preterm infants in the NICU throughout two intervention phases-- one in which each mother will randomly receive either NR or a placebo, then the opposite treatment-- to determine the effect of maternal NR supplementation on expressed milk volume and other markers of metabolism.

开始日期2024-12-01

申办/合作机构

University of California, Davis

NCT06324877 / Not yet recruitingN/AIIT

Single Arm Open-label Clinical Trial in Ataxia-telangiectasia to Test the Effects of Nicotinamide Riboside on Ataxia Scales, Immune Function, and Neurofilament Light Chain.

Study design: Single arm open-label clinical trial in ataxia-telangiectasia to test the effects of nicotinamide riboside on ataxia scales, immune function, and neurofilament light chain. Study population: 6-10 patients with Ataxia-Telangiectasia. Dose: Nicotinamide riboside 25 mg/kg/day in 3 equal divided doses.
Primary endpoint: Scales for assessment and rating of ataxia (SARA), and International Cooperative Ataxia Rating Scale (ICARS). Improvement of at least ½ standard deviation in key clinical scales which includes either; a) significant improvement in total combined scores from the SARA and ICARS scales, and /or b) significant improvements any aspects of the SARA and ICARS scales individually, especially pertaining to; Postural and gait improvements, Improved syllable speed and articulation, Improved fine motor skills.
Secondary endpoints: Serum analysis of neurofilament light chain (Nfl), Type 1 Interferon (INFs) epigenetic signature

开始日期2024-05-01

申办/合作机构

The University of Queensland

100 项与烟酰胺核糖相关的临床结果

登录后查看更多信息

100 项与烟酰胺核糖相关的转化医学

登录后查看更多信息

100 项与烟酰胺核糖相关的专利（医药）

登录后查看更多信息

853

项与烟酰胺核糖相关的文献（医药）

2025-01-01·BIOSENSORS & BIOELECTRONICS

Quantitative dynamics of intracellular NMN by genetically encoded biosensor

Article

作者: Wang, Pei ; Yu, Qiuliyang ; Liu, Kaijing ; Cheng, Wenxiang ; Huang, Guan ; Chen, Liuqing

Nicotinamide mononucleotide (NMN) is the direct precursor and a major booster of NAD⁺ with increasing applications in NAD⁺- and aging-related pathologies. However, measuring live cell NMN dynamics was not possible, leaving key questions in NMN uptake and intracellular regulation unanswered. Here we developed genetically encoded bioluminescent and fluorescent sensors to quantify subcellular NMN in live cells by engineering specific NMN-responsive protein scaffolds fused to luciferase and fluorescent proteins. The sensor dissected the multimechanistic uptake of exogenous NMN and nicotinamide riboside (NR) in live cells and further measured the NMN levels across different subcellular compartments, as well as the perturbed NMN/NAD⁺ ratios by external supplements. Moreover, we measured the NMN regulation by NAD(H) hydrolase Nudts and peroxisomal carrier Pxmp2 and identified Slc25a45 as a potential mitochondrial NMN regulator for its unique fingerprint on the local NMN/NAD⁺ ratio. Collectively, the genetically encoded sensors provide a useful tool for visualizing NMN metabolism.

2025-01-01·JOURNAL OF PATHOLOGY

Nicotinamide riboside targets mitochondrial unfolded protein response to reduce alcohol‐induced damage in Kupffer cells

Article

作者: Lee, Ji‐Young ; Kang, Hyunju ; Park, Young‐Ki ; Woo, Hayoung ; Lee, Jaeeun

Abstract:

The pathogenesis of alcohol‐related liver disease (ALD) is closely linked to mitochondrial dysfunction and impaired cellular energy metabolism. In this study, we explored how ethanol triggers inflammation, oxidative stress, and mitochondrial dysfunction in Kupffer cells, i.e.hepatic resident macrophages, primarily focusing on the mitochondrial unfolded protein response (UPRmt) using immortalized mouse Kupffer cells (ImKCs) and mouse primary KCs. The UPRmt is a cellular defense mechanism activated in response to the perturbation of mitochondrial proteostasis to maintain mitochondrial integrity and function by upregulating the expression of mitochondrial chaperones and proteases. We also determined whether nicotinamide riboside (NR), a NAD+ precursor, could mitigate ethanol‐triggered cellular damage. When ImKCs were exposed to 80 mm ethanol for 72 h, they displayed inflammation, oxidative stress, and impaired mitochondrial function with decreased mitochondrial content and deformed mitochondrial crista structure. NR, however, counteracted the effects of ethanol. Furthermore, ethanol increased mRNA and protein levels of UPRmt genes, such as mitochondrial chaperones and proteases, which were attenuated by NR. Notably, the ethanol‐induced shift in the entry of activating transcription factor 5 (ATF5), a putative transcriptional regulator of UPRmt, to the nucleus from the mitochondria was abolished by NR. The induction of UPRmt genes by ethanol was significantly repressed when Atf5 was knocked down, indicating the role of ATF5 in the induction of UPRmt genes in ImKCs exposed to ethanol. We also confirmed the induction of UPRmt gene expression in mouse and human livers exposed to alcohol. Our findings demonstrate the ability of NR to alleviate ethanol‐induced oxidative stress, inflammation, and mitochondrial dysfunction, partly by modulating the ATF5‐dependent UPRmt pathway in ImKCs, suggesting its potential for ALD therapy. © 2024 The Pathological Society of Great Britain and Ireland.

2025-01-01·FREE RADICAL BIOLOGY AND MEDICINE

Restoration of mitochondrial function alleviates trigeminal neuropathic pain in mice

Article

作者: Yang, Jiajun ; Zhang, Yi ; Yang, Yaning ; Zhou, Yujuan ; Chen, Xing ; Guo, Jiahao ; Fan, Yuanlan ; Sun, Zhaoxia ; Cai, Peng ; Xie, Song ; Cao, Xuxia ; Jiang, Shangying ; Li, Xiaokun ; Zhang, Chenchen

Craniofacial pain is prevalent and a debilitating condition. Managing craniofacial pain is particularly challenging due to its multifaceted nature. Among the most severe forms of craniofacial pain is trigeminal neuralgia, often described as one of the most excruciating pain syndromes encountered in clinical practice. Utilizing a mouse model of trigeminal neuropathic pain, we found severe mitochondrial impairment in the injured trigeminal ganglion (TG), spanning transcription and translation to functionality. Our findings demonstrated that rejuvenating mitochondria by boosting NAD⁺ levels enhanced mitochondrial fitness and significantly ameliorated trigeminal neuropathic pain. Additionally, we showed that the analgesic effects of nicotinamide riboside (NR) supplementation mainly depend on Sirt1. Importantly, our multi-omics studies revealed that activated Sirt1 by NR suppresses a broad range of key pain genes and exerts anti-inflammatory effects in the TG. Together, we present a comprehensive view of how mitochondrial dysfunction is involved in trigeminal neuropathic pain. Therefore, targeting mitochondrial dysfunction offers a novel and promising approach to craniofacial pain management.

69

项与烟酰胺核糖相关的新闻（医药）

2024-11-22

·drugs

Could a Vitamin Be Effective Treatment for COPD?

FRIDAY, Nov. 22, 2024 -- A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD , Danish researchers report. "This is significant, because inflammation can lead to reduced lung function in these patients," said researcher Morten Scheibye-Knudsen , of the University of Copenhagen. Patients with COPD -- the full name of which is chronic obstructive pulmonary disease -- are more likely to get pneumonia, influenza and other serious respiratory infections, which can be fatal. The new study included 40 participants with COPD and a control group of 20 healthy volunteers. They received either 2 grams a day of nicotinamide riboside -- a member of the vitamin B3 family -- or a placebo. After six weeks, researchers saw a 53% drop in a marker of inflammation known as interleukin 8, or IL 8. After 12 more weeks of vitamin therapy, the effect increased by 63%. "In other words," the researchers said in a university news release, "The group treated with vitamin B3 experienced reduced lung inflammation during the study." More study will be needed to confirm the findings and determine the long-term effect of nicotinamid riboside in treating COPD, Scheibye-Knudsen said. During the study, the team also observed that COPD patients have lower blood levels of a chemical called NAD, which appears to play a role in the aging process. NAD levels rose with vitamin B3 treatment and signs of cellular aging slowed, researchers reported Nov. 15 in the journal Nature Aging . "As we age, we seem to metabolize a molecule known as NAD," Scheibye-Knudsen said. "The loss of this molecule is also seen after DNA damage, for instance the type of damage associated with smoking." As such, he said NAD may be a target for future research and treatment. Meanwhile, his team plans a larger study to confirm the initial findings. "We hope this research will pave the way for new treatment options for COPD patients," Scheibye-Knudsen said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2024-11-18

·生物世界

Nature Aging：人体临床试验显示，补充烟酰胺可改善衰老相关肺部

撰文丨王聪编辑丨王多鱼排版丨水成文衰老（Aging）是慢性疾病发生发展的最重要的危险因素之一，而慢性阻塞性肺疾病（COPD）则是一种肺部加速衰老的疾病。烟酰胺腺嘌呤二核苷酸（NAD+）是一种参与多种年龄相关通路的中心分子，包括免疫功能和炎症。重要的是，在人类、各种动物模型和早衰性疾病中，NAD+调节DNA修复能力随着年龄的增长而降低。烟酰胺核苷（Nicotinamide riboside，NR）是一种NAD+的前体物质，可减轻衰老功能障碍，在动物模型中，即使短期使用NR治疗也可挽救DNA修复障碍。在人类中，调控NAD+水平可能改善胰岛素抵抗和帕金森病的一些特征。尽管一些研究的结果差强人意，但烟酰胺核苷（NR）的抗炎作用是迄今为止最一致的发现。而在慢性阻塞性肺疾病（COPD）中增加NAD+水平的影响尚未被研究。 2024年11月15日，丹麦哥本哈根大学的研究人员在 Nature 子刊 Nature Aging 上发表了题为：Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial 的研究论文。这项随机、双盲、安慰剂对照临床试验结果显示，补充NAD+前体烟酰胺核苷（NR）在肺部健康者和慢性阻塞性肺疾病（COPD）中安全且耐受性良好，降低了COPD患者的气道炎症，增加了全血中的NAD+水平。这些结果表明，NR可能是COPD患者的一种可行的治疗选择。慢性阻塞性肺疾病（COPD）是一种与吸烟和高龄相关的进行性、不可治愈的疾病，是全球第三大死亡原因。烟酰胺腺嘌呤二核苷酸（NAD+）参与一系列重要的生物学过程，包括细胞增殖和分化、能量代谢、DNA损伤修复、表观遗传修饰、细胞衰老、炎症、昼夜节律等重要生理活动。体内的NAD+水平会随着年龄的增长而逐渐耗竭， NAD+耗竭是衰老及衰老相关疾病的重要标志。 DNA损伤和NAD+的减少可能与衰老和COPD均有关联，这为干预提供了潜在途径。在该研究中，研究团队推测，在既往吸烟的COPD患者中增加NAD+水平（通过补充NAD+的前体NR）可以减少气道炎症和细胞衰老，并导致与DNA修复相关的转录通路上调。 NAD+的生物合成：NR（烟酰胺核苷），NMN（烟酰胺单核苷酸），NAD+（烟酰胺腺嘌呤二核苷酸）为了研究这一点，研究团队进行了一项随机、双盲、安慰剂对照临床试验，在该试验中，非嗜酸性粒细胞性COPD患者（40名）和肺部健康对照者（18名）每天补充NAD+前体烟酰胺核苷（NR）（每天2次，每次1克）或安慰剂，持续6周时间，并在12周后进行随访。由于白介素-8（IL-8）是衰老相关分泌表型（SASP）的一部分，并且是COPD患者的中性粒细胞增多的驱动因素，因此该临床试验选择了这一细胞因子水平作为主要结局。结果显示，对于主要结局，参与者的痰白细胞介素-8 （IL-8）从基线至第6周时发生变化，6周后，治疗组和安慰剂组在IL-8方面的估计差异为-52.6%，这一效应持续至治疗结束后12周的随访（-63.7%）。对于次要结局，NR治疗使全血中的NAD+水平增加了2倍以上，而血浆中的IL-6水平保持不变。在探索性分析中，NR治疗显示与气道中基因组完整性相关的基因通路上调，并减少表观遗传衰老（可能是通过减少细胞衰老实现的）。总的来说，这项研究表明，补充NAD+前体烟酰胺核苷（NR）降低了气道炎症，增加了全血中的NAD+水平。在探索性分析中，NR治疗显示与气道中基因组完整性相关的基因通路上调，并减少表观遗传衰老。此外，在肺部健康的对照组和COPD患者中，每天补充2克NR均被证明是安全且耐受性良好的。这些结果表明，NR可能是COPD患者的一种可行的治疗选择。论文链接： https://www-nature-com.libproxy1.nus.edu.sg/articles/s43587-024-00758-1 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

寡核苷酸临床结果

2024-09-26

·Business Wire

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

LOS ANGELES--( BUSINESS WIRE )--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors. Company Webcast The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at https://app.webinar.net/7yrd0odReoK or on the Company's website at chromadex.com. The webcast will also be available for replay following the event. 1x1 Meetings Mr. Fried and Mr. Yu will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg . Further information on the conference is available at https://lythampartners.com/fall2024 . For additional information on ChromaDex, visit www.chromadex.com . About ChromaDex: ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen ® , the number one healthy-aging NAD+ supplement in the United States † . Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com ). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com , to which ChromaDex regularly publishes copies of its press releases, news, and financial information. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

寡核苷酸

100 项与烟酰胺核糖相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	烟酰胺核糖	A11HA01	DB14933

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头颈部肿瘤	临床2期	美国	ChromaDex, Inc.	2019-11-08
转移性乳腺癌	临床2期	美国	ChromaDex, Inc.	2019-11-08
转移性子宫内膜恶性肿瘤	临床2期	美国	ChromaDex, Inc.	2019-11-08
周围神经系统疾病	临床2期	美国	ChromaDex, Inc.	2019-11-08
铂耐药性卵巢癌	临床2期	美国	ChromaDex, Inc.	2019-11-08
急性发热性疾病	临床2期	挪威	ChromaDex, Inc.	2019-10-01
危重病	临床2期	挪威	ChromaDex, Inc.	2019-10-01
炎症	临床2期	挪威	ChromaDex, Inc.	2019-10-01
共济失调毛细血管扩张	临床2期	挪威	Akershus Universitetssykehus HF	2019-06-05
外周动脉疾病	临床2期	-	ChromaDex, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Biospace 人工标引	临床2期	外周动脉疾病	90	Nicotinamide Riboside	簾夢餘齋膚襯簾齋顧衊(齋網夢製範鹽壓糧襯觸) = 積襯構餘廠製襯簾廠範壓糧襯廠願願憲構蓋壓 (壓齋鹹積鹹構簾鑰齋淵 )	积极	2024-06-24
				Nicotinamide Riboside combination with resveratrol	-
NCT03912220 (CTgov)	临床2期	小纤维神经病变	45	Nicotinamide riboside (Nicotinamide Riboside)	鹽窪蓋繭鏇糧齋範願願(艱製範願築遞艱衊繭鏇) = 製窪艱繭齋獵網窪鹹網選齋鹹範鹹淵積衊願製 (獵簾襯遞鏇築壓觸艱餘, 壓鏇醖廠鹹願齋齋簾窪 ~ 願餘選築夢範鑰遞觸獵) 更多	-	2024-06-06
				Placebo Oral Tablet (Placebo)	鹽窪蓋繭鏇糧齋範願願(艱製範願築遞艱衊繭鏇) = 憲鹽蓋廠醖獵顧餘餘鬱選齋鹹範鹹淵積衊願製 (獵簾襯遞鏇築壓觸艱餘, 鬱鏇選觸廠夢獵獵廠膚 ~ 膚憲鑰網鏇鑰糧鬱顧廠) 更多
ATS2024	N/A	脓毒症	-	Nicotinamide Riboside (NR) 30 mg/kg	構醖鏇糧憲憲鏇餘構鬱(鬱遞鹽窪顧範顧簾構積) = 齋艱製鑰窪鹹繭獵鹹蓋淵構願醖願齋憲簾鏇願 (廠積鹹糧廠範範鹽獵糧 )	-	2024-05-19
				H2O control	構醖鏇糧憲憲鏇餘構鬱(鬱遞鹽窪顧範顧簾構積) = 憲願製糧衊鬱淵蓋齋構淵構願醖願齋憲簾鏇願 (廠積鹹糧廠範範鹽獵糧 )
NCT04818216 (NIRVANA, CTgov)	临床2期	新型冠状病毒感染 \| 急性肾损伤	28	Placebo (Placebo Group)	獵構遞觸蓋構齋顧觸壓(鹽夢網願窪蓋繭範鑰構) = 獵觸鏇構遞鹹鏇網壓醖製積願蓋築範淵夢壓願 (製獵範鑰糧糧鹽廠網醖, 鹽醖構夢憲齋範糧襯鬱 ~ 餘遞醖窪蓋齋鏇遞蓋鏇) 更多	-	2023-12-26
				Nicotinamide riboside (Nicotinamide Riboside Group)	獵構遞觸蓋構齋顧觸壓(鹽夢網願窪蓋繭範鑰構) = 壓鹽鏇遞壓淵鏇鑰製壓製積願蓋築範淵夢壓願 (製獵範鑰糧糧鹽廠網醖, 願範範憲獵繭夢襯廠觸 ~ 餘構蓋夢簾製窪鹽夢襯) 更多
Biospace 人工标引	临床1期	帕金森病	20	Niagen 3000 mg	艱壓廠鹹鏇積壓窪糧範(鬱膚糧廠夢構選醖鏇鹽) = High-dose NR was safe and well-tolerated with no related adverse events. 淵鹽鹽膚選顧壓觸窪鏇 (淵鑰夢醖觸鹽鬱遞獵選 ) 更多	积极	2023-11-30
				placebo
ARVO2023	临床2期	青光眼 nicotinamide adenine dinucleotide (NAD)	118	Nicotinamide Riboside (NR) 300mg/day	壓憲衊觸醖製鏇選願選(鑰網鹹繭範鏇蓋築壓構) = Two patients, one in each group, developed gastrointestinal upset 淵觸糧糧糧選壓襯簾獵 (製願範範鹽糧觸夢襯衊 )	积极	2023-06-01
NCT03642990 (CTgov)	临床2期	转移性子宫内膜恶性肿瘤 \| 转移性乳腺癌 \| 周围神经系统疾病 ... 更多	5	Nicotinamide Riboside	製夢膚蓋繭壓繭壓鹹鬱(遞襯鏇鹽蓋憲鹹膚網廠) = 窪鹽鏇願餘構願窪選選築餘淵憲遞網範繭糧遞 (構積餘鏇鹹窪壓築製襯, 獵夢簾願鏇觸窪積構鹽 ~ 觸膚繭壓顧構製獵網鹹) 更多	-	2023-04-12
ESC2021	N/A	-	-	Nicotinamide Riboside	選蓋構範鹹醖醖鹽醖鹹(鹹齋構襯構齋觸製鏇廠) = 糧壓艱鏇鏇網鹽積壓簾鬱餘鑰製築糧衊遞獵鏇 (餘鏇範鹽衊繭鹽衊鑰鏇 )	-	2021-08-27
Pubmed \| PLoS One	N/A	NADH/NAD+	8	Nicotinamide Riboside 250 mg	壓夢鹹襯遞廠願繭願齋(餘艱衊鬱獵齋糧襯廠鹹) = Oral Not reached was well tolerated with no adverse events 顧網積積鏇壓廠簾夢餘 (簾衊觸膚選網鹽構積築 ) 更多	积极	2017-12-06
				Nicotinamide Riboside 1000 mg